drugset / Trial / NCT03532542
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
Timeline
- Start
- 2018-08-02
- Primary completion
- 2023-07-26
- Completion
- 2023-07-26
Outcome
Outcome not reported
Stopped: “The trial was stopped to reduce the clinical trial burden on participants while ensuring continued treatment via a post-trial access program with commercially available casimersen and golodirsen. Study was not terminated due to safety concerns.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Casimersen | Unknown | 30 mg/kg | Intravenous |
| Subject | Golodirsen | Unknown | 30 mg/kg | Intravenous |